Qilu Drug R&D Institute has been enlisted by the relevant state bureau as a National Certified Technology Center and National Engineering Laboratory for Bio-technology.

Qilu has wisely invested in the employment of about 600 qualified employees to carry out the task of research and development. With good capital and state-of-the-art research facilities, Qilu has developed over 160 generics which have been launched in China. Another 100 generics are in the pipeline, almost 50% of which are oncology products.

Main therapeutic areas of drugs launched and those in the process:
♦ Oncology
♦ Infections
♦ Cerebrovascular & Cardiovascular Diseases
♦ Psychological and Neurological Diseases